<DOC>
	<DOCNO>NCT03043547</DOCNO>
	<brief_summary>open label , randomize , multicenter phase II trial</brief_summary>
	<brief_title>Nal-IRI 5-FU Compared 5-FU Patients With Cholangio- Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies</brief_title>
	<detailed_description>The primary objective ass efficacy nal-IRI gemcitabine pre-treated patient advance , unresectable metastatic cholangio- gallbladder carcinoma eligible treatment failure respond gemcitabine-based treatment</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Written inform consent incl . participation translational research locallyrequired authorization ( EU Data Privacy Directive EU ) obtain subject prior performing protocolrelated procedure , include screen evaluation 2 . Age ≥ 18 year time study entry 3 . Histologically cytologically confirm , nonresectable , locally advanced metastatic cholangiocarcinoma gall bladder carcinoma 4 . Measurable assessable disease accord RECIST 1.1 5 . Documented disease progression prior gemcitabine gemcitabine contain therapy , locally advanced metastatic setting . Examples permit therapy include , limited : 1 . Single agent gemcitabine 2 . Any one gemcitabinebased regimen , without maintenance gemcitabine 6 . ECOG performance status 01 7 . Adequate blood count , liverenzymes , renal function : ANC &gt; 1,500 cells/μL without use hematopoietic growth factor ; Platelet count ≥ 100 x 10^9/L ( &gt; 100,000 per mm³ ) Hemoglobin &gt; 9 g/dL ( blood transfusion permit patient hemoglobin level 9 g/dL ) Serum total bilirubin ≤ 3x upper normal limit ( ULN ) ( biliary drainage allow biliary obstruction ; elevate bilirubin cause obstruction impair liver function assess albumin INR value ) : Albumin level ≥ 3.0 g/dL Patients receive therapeutic anticoagulation must INR &lt; 1.5 ULN PTT &lt; 1.5 ULN within 7 day prior randomization . The use full dose anticoagulant allow long INR PTT within therapeutic limit ( accord medical standard institution ) patient stable dose anticoagulant least three week time randomization AST ( SGOT ) /ALT ( SGPT ) ≤ 5 x institutional upper limit normal Serum Creatinine ≤ 1.5 x ULN calculate glomerular filtration rate ≥ 30 mL per minute 8 . Female patient reproductive potential must negative urine serum pregnancy test within 7 day prior start treatment . 9 . Subject willing able comply protocol ( include contraceptive measure ) duration study include undergoing treatment schedule visit examination include follow . 1 . Active CNS metastasis ( indicated clinical symptom , cerebral oedema , steroid requirement , progressive disease ) ; patient steroid least 28 day prior start study therapy 2 . Clinically significant gastrointestinal disorder include bleeding , inflammation , occlusion , diarrhoea &gt; grade 1 3 . History second malignancy last 5 year ; subject prior history insitu cancer basal squamous cell skin cancer eligible . Subjects malignancy eligible continuously disease free least 5 year . 4 . Active uncontrolled infection , chronic infectious disease , immune deficiency syndrome unexplained fever &gt; 38.5°C screen visit first schedule day dose ( discretion investigator , patient tumour fever may enrol ) , investigator 's opinion might compromise patient 's participation trial affect study outcome . 5 . Premalignant hematologic disorder , e.g . myelodysplastic syndrome 6 . Preexisting lung disease 7 . Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) 6 month enrollment 8 . History hypersensitivity study drug excipient ( nalIRI , liposomal product , fluoropyrimidines leucovorin ) 9 . Allogeneic transplantation require immunosuppressive therapy major immunosuppressive therapy 10 . Severe nonhealing wound , ulcer bone fraction 11 . Evidence bleed diathesis coagulopathy 12 . Major surgical procedure , except open biopsy , significant traumatic injury within 28 day prior randomization , anticipation need major surgical procedure course study except surgery central intravenous line placement chemotherapy administration . 13 . Medication know interfere agent apply trial . 14 . Female subject pregnant , breastfeed male female patient reproductive potential employ effective method birth control ( failure rate le 1 % per year ) . [ Acceptable method contraception : implant , injectable contraceptive , combine oral contraceptive , intrauterine pessary ( hormonal device ) , sexual abstinence vasectomy partner ] . 15 . Known GilbertMeulengracht syndrome 16 . Any condition comorbidity , opinion investigator , would interfere evaluation study treatment interpretation patient safety study result 17 . Participation another clinical study investigational product last 30 day inclusion 5 halflifes previously use trial medication , whichever long duration . 18 . Previous enrollment randomization present study ( include screen failure ) . 19 . Previous enrollment NIFE trial [ AIOYMO/HEP0315 ] 20 . Involvement plan and/or conduct study ( applies Baxalta staff and/or staff sponsor study site ) 21 . Patient might dependent sponsor , site investigator 22 . Patient incarcerate involuntarily institutionalize court order authority § 40 Abs . 1 S. 3 Nr . 4 AMG . 23 . Patients unable consent understand nature , significance implication clinical trial therefore form rational intention light fact [ § 40 Abs . 1 S. 3 Nr . 3a AMG ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>nal-IRI</keyword>
	<keyword>5-Fluorouracil</keyword>
</DOC>